BTK
Los inhibidores de la tirosina quinasa de Bruton (BTK) son compuestos que específicamente se dirigen e inhiben la BTK, una enzima crucial involucrada en la señalización del receptor de células B y en la regulación de la angiogénesis. La BTK desempeña un papel significativo en la proliferación y supervivencia de las células cancerosas, particularmente en las malignidades hematológicas. Al inhibir la BTK, estos compuestos pueden interrumpir la angiogénesis y el crecimiento tumoral, lo que los convierte en valiosos en la terapia contra el cáncer. En CymitQuimica, ofrecemos una gama de inhibidores de BTK de alta calidad para apoyar su investigación en oncología, inmunología y angiogénesis.
Se han encontrado 146 productos de "BTK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
GDC-0834 S-enantiomer
CAS:<p>GDC-0834, the S-enantiomer, is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK).</p>Fórmula:C33H36N6O3SPureza:98%Forma y color:SolidPeso molecular:596.74CHMFL-EGFR-202
CAS:<p>CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases).</p>Fórmula:C25H24ClN7O2Pureza:99.66%Forma y color:SolidPeso molecular:489.96(±)-Zanubrutinib
CAS:<p>(±)-Zanubrutinib ((±)-BGB-3111) is a potent and orally available Bruton's tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability,</p>Fórmula:C27H29N5O3Pureza:99.09%Forma y color:SolidPeso molecular:471.55NX-2127
CAS:<p>NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferative</p>Fórmula:C39H45N9O5Pureza:99.07%Forma y color:SolidPeso molecular:719.83(R)-Zanubrutinib
CAS:<p>(R)-Zanubrutinib ((R)-BGB-3111) is a selective inhibitor of Bruton tyrosine kinase (BTK).</p>Fórmula:C27H29N5O3Pureza:99.55%Forma y color:SolidPeso molecular:471.55Tilfrinib
CAS:<p>Tilfrinib is an effective and selective inhibitor of breast tumor kinase(Brk, IC50 = 3.15 nM) which displays anti-proliferative and anti-tumor activities.</p>Fórmula:C17H13N3OPureza:99.54%Forma y color:SolidPeso molecular:275.3(Rac)-PF-06250112
CAS:<p>(Rac)-PF-0625011 is a racemic mix, orally active, selective BTK inhibitor, also targeting BMX and TEC kinases.</p>Fórmula:C22H20F2N6O2Pureza:98%Forma y color:SolidPeso molecular:438.43BTK-IN-19
CAS:<p>BTK-IN-19 is a reversible BTK inhibitor with an IC 50 of <0.001 μM .</p>Fórmula:C21H22Cl2N6OForma y color:SolidPeso molecular:445.35BTK inhibitor 20
CAS:<p>BTK inhibitor 20 is a potent BTK inhibitor with an IC 50 of 8 nM .</p>Fórmula:C37H42N8O4Forma y color:SolidPeso molecular:662.78BTK-IN-18
CAS:<p>BTK-IN-18 is a potent, reversible inhibitor of Bruton's tyrosine kinase (BTK) with an inhibitory concentration (IC50) of 0.002 µM.</p>Fórmula:C20H22Cl2N6OForma y color:SolidPeso molecular:433.33BTK-IN-17
<p>BTK-IN-17: selective, oral BTK inhibitor, IC50=13.7 nM, reduces p-BTK Y223/p-PLCγ2 Y1217, anti-inflammatory.</p>Fórmula:C26H23N7O2Forma y color:SolidPeso molecular:465.51BTK-IN-11
CAS:<p>BTK-IN-11: potent BTK inhibitor; may research autoimmune, inflammatory diseases, cancer. (Patent WO2022063101A1, Z2)</p>Fórmula:C26H22ClN5O3Forma y color:SolidPeso molecular:487.94PF-303
CAS:<p>PF-303, a reversible covalent BTK inhibitor, shows potential for cancer and autoimmune therapy.</p>Fórmula:C22H21ClN6O2Forma y color:SolidPeso molecular:436.89BTK inhibitor 13
CAS:<p>BTK inhibitor 13 (compound 8) is an effective and selective BTK inhibitor(IC50: 1.2 nM).</p>Fórmula:C29H26FN5O3Pureza:98%Forma y color:SolidPeso molecular:511.55Pirtobrutinib
CAS:<p>Pirtobrutinib: a selective, non-covalent BTK inhibitor effective against BTK C481 mutations, causing tumor regression in lymphoma models.</p>Fórmula:C22H21F4N5O3Pureza:99.76% - 99.94%Forma y color:SolidPeso molecular:479.43Cinsebrutinib
CAS:<p>Cinsebrutinib, a Bruton's tyrosine kinase inhibitor, holds potential for research in cancer treatment.</p>Fórmula:C22H26FN3O2Pureza:98%Forma y color:SolidPeso molecular:383.46Edralbrutinib
CAS:<p>Edralbrutinib (TG-1701) is a potent BTK inhibitor with anticancer activity and is used in the treatment of tumors, immune system disorders, and blood and</p>Fórmula:C26H21F2N5O3Pureza:99.41%Forma y color:SolidPeso molecular:489.47BMX-IN-1
CAS:<p>BMX-IN-1 (BMX kinase inhibitor) is a selective inhibitor of bone marrow tyrosine kinase on chromosome X (BMX, IC50 = 8 nM) and the related Bruton’s tyrosine</p>Fórmula:C29H24N4O4SPureza:98.38%Forma y color:SolidPeso molecular:524.59PF-06250112
CAS:<p>PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM.</p>Fórmula:C22H20F2N6O2Pureza:98%Forma y color:SolidPeso molecular:438.43TAK-020
CAS:<p>TAK-020 is a potent covalent inhibitor of Btk with potential antitumor activity for the study of rheumatoid arthritis and immune-related diseases.</p>Fórmula:C18H17N5O3Pureza:98.79%Forma y color:SolidPeso molecular:351.36
